Fulcrum Therapeutics Inc (FULC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 80,000 | 2,805 | 6,342 | 19,163 | 8,823 |
| Gross Profit | 80,000 | 2,805 | 6,342 | 19,163 | 8,823 |
| Operating Expenses | 101,897 | 113,469 | 118,903 | 100,217 | 80,434 |
| Operating Income | -21,897 | -110,664 | -112,561 | -81,054 | -71,611 |
| Other Income | 12,172 | 13,329 | 2,690 | 207 | 792 |
| Pre-tax Income | -9,725 | -97,335 | -109,871 | -80,847 | -70,819 |
| Net Income Continuous | -9,725 | -97,335 | -109,871 | -80,847 | -70,819 |
| Net Income | $-9,725 | $-97,335 | $-109,871 | $-80,847 | $-70,819 |
| EPS Basic Total Ops | -0.16 | -1.59 | -2.44 | -2.29 | -2.79 |
| EPS Basic Continuous Ops | -0.16 | -1.59 | -2.44 | -2.29 | -2.79 |
| EPS Diluted Total Ops | -0.16 | -1.59 | -2.44 | -2.29 | -2.79 |
| EPS Diluted Continuous Ops | -0.16 | -1.59 | -2.44 | -2.29 | -2.79 |
| EPS Diluted Before Non-Recurring Items | -0.16 | -1.59 | -2.44 | -2.29 | -2.79 |
| EBITDA(a) | $-20,304 | $-108,492 | $-110,147 | $-78,539 | $-69,232 |